IMRX Stock Price, Immuneering Corporation Quote, Chart

Market Summary

USD1.48-0.06

Delayed

-3.90%

IMRX Stock Price

View Fullscreen

IMRX RSI Chart

IMRX Valuation

Market Cap

43.5M

Price/Earnings (Trailing)

-0.8

Price/Sales (Trailing)

145.48

EV/EBITDA

0.4

Price/Free Cashflow

-0.86

IMRX Price/Sales (Trailing)

IMRX Profitability

Operating Margin

100.00%

EBT Margin

-15937.29%

Return on Equity

-68.82%

Return on Assets

-61.57%

Free Cashflow Yield

-115.93%

IMRX Fundamentals

IMRX Revenue

Revenue (TTM)

317.0K

IMRX Earnings

Earnings (TTM)

-54.2M

Earnings Growth (Yr)

-5.17%

Earnings Growth (Qtr)

5.14%

Breaking Down IMRX Revenue

Last 7 days

2.1%

Last 30 days

-20.4%

Last 90 days

-77.6%

Trailing 12 Months

-83.5%

How does IMRX drawdown profile look like?

IMRX Financial Health

Current Ratio

14.38

IMRX Investor Care

Shares Dilution (1Y)

11.07%

Diluted EPS (TTM)

-1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	1.5M	949.8K	506.1K	317.0K
2021	2.3M	2.2M	2.1M	2.1M
2020	0	0	0	2.3M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Immuneering Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	cormorant asset management, lp	sold	-1,160,180	2.90045	-400,000	-
Mar 22, 2024	morales mallory	bought	1,000	2.5455	393	chief accounting officer
Mar 22, 2024	feinberg peter	bought	63,712	2.5485	25,000	-
Mar 22, 2024	schall thomas j.	bought	7,384	2.5465	2,900	-
Mar 22, 2024	brakewood harold eugene	bought	10,015	2.568	3,900	chief business officer
Mar 21, 2024	morales mallory	bought	3,008	2.7179	1,107	chief accounting officer
Mar 20, 2024	neufeld leah r	bought	10,993	2.8793	3,818	chief people officer
Mar 20, 2024	hall brett matthew	bought	20,020	2.86	7,000	chief scientific officer
Mar 19, 2024	zeskind benjamin j.	bought	55,326	2.7663	20,000	president and ceo
Mar 19, 2024	feinberg peter	bought	64,000	2.56	25,000	-

Which funds bought or sold IMRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-31.02	-19,739	7,346	-%
May 16, 2024	JANE STREET GROUP, LLC	new	-	38,836	38,836	-%
May 15, 2024	Oracle Alpha Inc.	reduced	-5.33	-54,419	32,267	0.06%
May 15, 2024	Cormorant Asset Management, LP	reduced	-21.62	-21,378,700	9,523,340	0.42%
May 15, 2024	SOUTHPORT MANAGEMENT, L.L.C.	added	258	75,904	260,389	0.96%
May 15, 2024	Tower Research Capital LLC (TRC)	added	123	-1,919	14,141	-%
May 15, 2024	HighVista Strategies LLC	unchanged	-	-1,135,130	735,543	0.26%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	453	98,758	182,827	-%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	reduced	-50.00	-590,500	144,500	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	192	42,592	329,602	0.01%

Are Funds Buying or Selling IMRX?

Are funds buying IMRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IMRX

No. of Funds

Unveiling Immuneering Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 15, 2024	cormorant asset management, lp	1.92%	561,128	SC 13G/A
Apr 10, 2024	price t rowe associates inc /md/	3.1%	910,266	SC 13G/A
Apr 05, 2024	blackrock inc.	4.7%	1,377,120	SC 13G/A
Mar 27, 2024	merrin investors llc	9.46%	2,770,386	SC 13G/A
Feb 14, 2024	price t rowe associates inc /md/	11.5%	3,378,100	SC 13G/A
Feb 14, 2024	citadel advisors llc	7.0%	6	SC 13G/A
Jan 26, 2024	blackrock inc.	7.2%	2,097,406	SC 13G
Jan 16, 2024	zeskind benjamin j.	12.6%	3,687,142	SC 13G/A
May 05, 2023	blackrock inc.	4.6%	1,336,436	SC 13G/A
Apr 24, 2023	cormorant asset management, lp	6.85%	1,996,779	SC 13G/A

Recent SEC filings of Immuneering Corporation

View All Filings

Date Filed	Form Type	Document
May 07, 2024	10-Q	Quarterly Report
May 07, 2024	8-K	Current Report
Apr 23, 2024	DEF 14A	DEF 14A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 15, 2024	SC 13G/A	Major Ownership Report
Apr 10, 2024	SC 13G/A	Major Ownership Report
Apr 05, 2024	SC 13G/A	Major Ownership Report
Apr 03, 2024	4	Insider Trading
Mar 27, 2024	SC 13G/A	Major Ownership Report
Mar 25, 2024	4	Insider Trading

Peers (Alternatives to Immuneering Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Immuneering Corporation News

Latest updates

Immuneering Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)											(In Thousands)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Revenue	-98.8%	455	38,380	94,419	183,698	189,591	482,130	660,040	748,200	715,385	682,570	480,835
Cost Of Revenue	-100.0%	-	19,343	47,933	90,846	206,221	219,088	318,601	409,163	-	315,002	237,062
Gross Profit	-97.6%	455	19,037	46,486	92,852	-16,630	263,042	341,439	339,037	-	367,568	243,773
Operating Expenses	5.9%	13,985,462	13,207,187	11,692,535	13,018,514	11,099,125	8,806,426	8,332,363	6,575,043	-	4,767,797	3,850,403
S&GA Expenses	7.2%	4,110,437	3,836,032	3,704,143	3,951,866	3,148,637	2,598,940	1,340,398	1,184,023	-	698,760	629,403
R&D Expenses	5.4%	9,867,710	9,363,838	7,981,075	9,058,545	7,950,488	6,207,486	6,991,965	5,391,020	-	4,069,037	3,221,000
EBITDA Margin	-138.5%	-158	-66.51	-35.49	-22.28	-16.25	-7.96	-7.75	-7.55	-7.36	-	-
EBT Margin	-138.3%	-159	-66.87	-35.63	-22.33	-16.27	-7.97	-7.76	-7.56	-7.37	-	-
Net Income	-3.1%	-13,245,561	-12,844,330	-11,527,303	-12,896,374	-10,784,359	-8,534,073	-7,987,665	-6,229,651	-5,835,937	-4,399,079	-3,604,162
Net Income Margin	-67.9%	-159	-94.95	-46.05	-26.53	-16.12	-13.37	-11.14	-8.91	-7.37	-	-
Free Cashflow	-7.3%	-11,817,916	-11,015,473	-9,614,270	-12,396,089	-9,252,042	-9,045,975	-6,457,247	-6,156,404	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-14.2%	88.00	103	114	125	108	122	134	142	152	167	164	53.00	38.00
Current Assets	-16.4%	74.00	89.00	101	112	94.00	109	120	129	140	152	153	51.00	38.00
Cash Equivalents	11.6%	66.00	59.00	68.00	104	77.00	73.00	76.00	88.00	75.00	75.00	107	50.00	37.00
Net PPE	-3.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00
Goodwill	0%	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	-	-	-
Liabilities	-22.9%	9.00	12.00	10.00	10.00	10.00	13.00	12.00	8.00	8.00	11.00	6.00	5.00	3.00
Current Liabilities	-34.0%	5.00	8.00	6.00	5.00	6.00	8.00	7.00	4.00	4.00	6.00	5.00	5.00	2.00
Shareholder's Equity	-13.1%	79.00	91.00	104	115	98.00	110	122	134	144	156	158	-	-
Retained Earnings	-8.8%	-177	-163	-148	-135	-123	-109	-96.54	-83.70	-72.17	-59.27	-48.49	-39.95	-25.74
Additional Paid-In Capital	1.0%	256	254	252	251	221	220	219	217	216	215	207	5.00	3.00
Shares Outstanding	3.4%	29.00	28.00	28.00	28.00	26.00	26.00	26.00	26.00	26.00	14.00	18.00	5.00	5.00
Float	-	-	-	-	239	-	-	-	112	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-31.6%	-15,491	-11,775	-12,026	-10,748	-14,418	-11,748	-10,622	-9,449	-12,281	-9,238	-9,034	-6,437	-6,139	-	-	-
Share Based Compensation	-10.1%	1,475	1,641	1,479	1,334	1,274	1,048	1,066	1,052	898	633	637	351	182	-	-	-
Cashflow From Investing	582.8%	21,393	3,133	-23,971	9,163	18,972	8,152	-880	22,154	12,405	-22,807	-52,771	-19.82	-16.56	-	-	-
Cashflow From Financing	12407.0%	980	8.00	21.00	28,172	239	-184	-17.21	28.00	193	8.00	118,489	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IMRX Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 11,202,414	$ 10,210,926
General and administrative	4,116,019	4,461,331
Amortization of intangible asset	7,317	7,317
Total operating expenses	15,325,750	14,679,574
Loss from operations	(15,325,750)	(14,679,574)
Other income (expense)
Interest income	804,884	831,274
Other income, net	213,037	244,129
Net loss	$ (14,307,829)	$ (13,604,171)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.49)	$ (0.51)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.49)	$ (0.51)
Weighted-average common shares outstanding, basic (in shares)	29,370,357	26,442,216
Weighted-average common shares outstanding, diluted (in shares)	29,370,357	26,442,216
Other comprehensive loss:
Unrealized gains (losses) from marketable securities	$ (306)	$ 30,626
Comprehensive Loss	$ (14,308,135)	$ (13,573,545)

IMRX Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 66,287,148	$ 59,405,817
Marketable securities	4,991,200	26,259,868
Prepaids and other current assets	3,169,089	3,417,984
Total current assets	74,447,437	89,083,669
Property and equipment, net	1,347,852	1,400,582
Goodwill	6,690,431	6,690,431
Intangible asset, net	372,363	379,680
Right-of-use assets, net	3,905,575	3,995,730
Other assets	1,219,182	1,034,446
Total assets	87,982,840	102,584,538
Current liabilities:
Accounts payable	2,270,862	2,111,666
Accrued expenses	2,584,359	5,173,960
Other liabilities	23,634	259,770
Lease liabilities	298,543	300,107
Total current liabilities	5,177,398	7,845,503
Long-term liabilities:
Lease liabilities, net of current portion	4,082,713	4,162,852
Total liabilities	9,260,111	12,008,355
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; 0 shares issued or outstanding at March 31, 2024 and December 31, 2023	0	0
Additional paid-in capital	256,260,567	253,806,267
Accumulated other comprehensive loss	(1,084)	(778)
Accumulated deficit	(177,566,407)	(163,258,578)
Total stockholders' equity	78,722,729	90,576,183
Total liabilities and stockholders' equity	87,982,840	102,584,538
Class A Common Stock
Stockholders’ equity:
Common stock	29,653	29,272
Class B Common Stock
Stockholders’ equity:
Common stock	$ 0	$ 0

About Immuneering Corporation

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

CEO	Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
WEBSITE	https://immuneering.com
INDUSTRY	Biotechnology
EMPLOYEES	66

Immuneering Corporation Frequently Asked Questions

What is the ticker symbol for Immuneering Corporation? What does IMRX stand for in stocks?

IMRX is the stock ticker symbol of Immuneering Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Immuneering Corporation (IMRX)?

As of Fri May 17 2024, market cap of Immuneering Corporation is 43.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IMRX stock?

You can check IMRX's fair value in chart for subscribers.

What is the fair value of IMRX stock?

You can check IMRX's fair value in chart for subscribers. The fair value of Immuneering Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Immuneering Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IMRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Immuneering Corporation a good stock to buy?

The fair value guage provides a quick view whether IMRX is over valued or under valued. Whether Immuneering Corporation is cheap or expensive depends on the assumptions which impact Immuneering Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IMRX.

What is Immuneering Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IMRX's PE ratio (Price to Earnings) is -0.8 and Price to Sales (PS) ratio is 145.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IMRX PE ratio will change depending on the future growth rate expectations of investors.